ASP Isotopes (ASPI) Projected to Announce Quarterly Earnings on Friday

Key Points

• ASP Isotopes is expected to report Q2 2026 results on August 14, with analysts forecasting a loss of $0.17 per share and revenue of approximately $4.47 million.
• In the prior quarter, the company reported a smaller-than-expected loss of $0.22 per share and revenue of $8.36 million, exceeding analyst estimates.
• The stock recently traded at $4.10, well below its 52-week high of $14.49. Analysts have a consensus “Hold” rating and an average price target of $13, while insiders have sold shares worth about $2.05 million over the past 90 days.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) is expected to post its Q2 2026 results before the market opens on Friday, August 14th. Analysts expect ASP Isotopes to announce earnings of ($0.17) per share and revenue of $4.4660 million for the quarter. Individuals can check the company's upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) last issued its earnings results on Wednesday, May 20th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.06. ASP Isotopes had a negative return on equity of 112.46% and a negative net margin of 644.40%.The firm had revenue of $8.36 million for the quarter, compared to analyst estimates of $3.68 million.

ASP Isotopes Stock Performance

NASDAQ:ASPI opened at $4.10 on Friday. ASP Isotopes has a 52-week low of $3.51 and a 52-week high of $14.49. The firm has a market cap of $628.57 million, a price-to-earnings ratio of -1.97 and a beta of 3.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.37 and a current ratio of 4.39. The business's fifty day moving average is $5.59 and its 200 day moving average is $5.56.

Wall Street Analysts Forecast Growth

ASPI has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of ASP Isotopes in a report on Wednesday, June 24th. Canaccord Genuity Group restated a "buy" rating and issued a $11.00 price objective on shares of ASP Isotopes in a research report on Tuesday, April 14th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $13.00.

Insider Buying and Selling at ASP Isotopes

In other ASP Isotopes news, Director Todd Wider sold 50,000 shares of ASP Isotopes stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $6.25, for a total transaction of $312,500.00. Following the completion of the sale, the director owned 722,247 shares of the company's stock, valued at $4,514,043.75. The trade was a 6.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Heather Kiessling sold 23,124 shares of the company's stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $6.28, for a total value of $145,218.72. Following the completion of the transaction, the chief financial officer owned 1,526,252 shares of the company's stock, valued at $9,584,862.56. The trade was a 1.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 279,079 shares of company stock valued at $2,049,208. 14.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Quantbot Technologies LP bought a new stake in shares of ASP Isotopes in the 3rd quarter worth approximately $34,000. BNP Paribas Financial Markets lifted its stake in ASP Isotopes by 84.9% in the second quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company's stock worth $41,000 after purchasing an additional 2,548 shares during the last quarter. Guggenheim Capital LLC purchased a new stake in ASP Isotopes during the fourth quarter valued at about $72,000. Caption Management LLC boosted its position in ASP Isotopes by 110.5% during the fourth quarter. Caption Management LLC now owns 13,800 shares of the company's stock valued at $74,000 after buying an additional 145,800 shares during the period. Finally, Steward Partners Investment Advisory LLC bought a new position in shares of ASP Isotopes during the fourth quarter valued at about $74,000. 16.80% of the stock is currently owned by institutional investors.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source